{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:05:58Z","timestamp":1785528358332,"version":"3.56.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2026.104702","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:44:30Z","timestamp":1776354270000},"page":"104702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-disciplinary management of advanced uterine sarcoma: a state of the art review"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1962-7893","authenticated-orcid":false,"given":"Geoffrey Alan","family":"Watson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7617-916X","authenticated-orcid":false,"given":"Fabio","family":"Murtas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-7454","authenticated-orcid":false,"given":"Marjan","family":"Rouzbahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Pulenzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harleen","family":"Toor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-3929","authenticated-orcid":false,"given":"Kathy","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Croke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoun Rachel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ijgc.2026.104702_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101992","article-title":"Uterine leiomyosarcoma","volume":"35","author":"Bogani","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib2","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1996.0185","article-title":"Uterine leiomyosarcoma: analysis of treatment failures and survival","volume":"62","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104702_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdp485","article-title":"Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy","volume":"21","author":"Penel","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.soc.2020.08.002","article-title":"Surgical management of sarcoma metastatic to liver","volume":"30","author":"Ecker","year":"2021","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2007.02.031","article-title":"Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma","volume":"106","author":"Giuntoli","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157645","article-title":"Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)","volume":"15","author":"P\u00e9rez-Fidalgo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104702_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jtcvs.2003.10.011","article-title":"Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients","volume":"127","author":"Anraku","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ygyno.2019.05.015","article-title":"Secondary surgical resection for patients with recurrent uterine leiomyosarcoma","volume":"154","author":"Cybulska","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gore.2014.10.003","article-title":"Complete remission achieved by oophorectomy for recurrent endometrial stromal sarcoma after laparoscopic morcellation","volume":"11","author":"Inoue","year":"2015","journal-title":"Gynecol Oncol Rep"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104702_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaoncol.2024.1796","article-title":"Stereotactic ablative radiotherapy for gynecological oligometastatic and oligoprogressive tumors","volume":"10","author":"Donovan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10185","key":"10.1016\/j.ijgc.2026.104702_bib12","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2026.104702_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/IJWH.S117754","article-title":"Uterine sarcoma - current perspectives","volume":"9","author":"Benson","year":"2017","journal-title":"Int J Womens Health"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2009.08.014","article-title":"Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles","volume":"115","author":"Ioffe","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.6004\/jadpro.2022.13.1.6","article-title":"Uterine leiomyosarcoma","volume":"13","author":"Byar","year":"2022","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","article-title":"Soft tissue and uterine leiomyosarcoma","volume":"36","author":"George","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104702_bib17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(09)70226-8","article-title":"Clinical management of uterine sarcomas","volume":"10","author":"Amant","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2017.12.009","article-title":"Systemic treatment in adult uterine sarcomas","volume":"122","author":"Desar","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"10028","key":"10.1016\/j.ijgc.2026.104702_bib20","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104702_bib21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104702_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-trabectedin with trabectedin maintenance in leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N Engl J Med"},{"issue":"9829","key":"10.1016\/j.ijgc.2026.104702_bib23","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104702_bib24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.23.02266","article-title":"Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update","volume":"42","author":"Wagner","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104702_bib25","article-title":"Alliance A092104: a randomized phase 2\/3 study of olaparib plus temozolomide versus investigator\u2019s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy","volume":"43","author":"Van Tine","year":"2025","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104702_bib26","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104702_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104702_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104702_bib30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2021.02.016","article-title":"Phase 2 study of anastrozole in patients with estrogen receptor\/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: the Paragon trial (ANZGOG 0903)","volume":"161","author":"Friedlander","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13569-015-0024-0","article-title":"Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital","volume":"5","author":"Thanopoulou","year":"2015","journal-title":"Clin Sarcoma Res."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejogrb.2009.02.005","article-title":"The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study","volume":"144","author":"Dahhan","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104702_bib41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.1985.3.9.1240","article-title":"A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study","volume":"3","author":"Omura","year":"1985","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib90","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0002-9378(92)91671-V","article-title":"Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"166","author":"Sutton","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib91","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1996.0220","article-title":"Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study","volume":"62","author":"Sutton","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104702_bib92","first-page":"1281","article-title":"Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas","volume":"30","author":"Haddox","year":"2024","journal-title":"Clinical Outcomes and Biological Correlates. Clin Cancer Res."},{"issue":"24","key":"10.1016\/j.ijgc.2026.104702_bib93","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma","volume":"30","author":"Movva","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104702_bib34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41379-021-01003-5","article-title":"ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment","volume":"35","author":"Dessources","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473106","article-title":"Rare uterine tumors: what to do?","volume":"45","author":"Crane","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.10.064","article-title":"Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors","volume":"116","author":"O\u2019Cearbhaill","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3329-4-5","article-title":"Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors","volume":"4","author":"Thanopoulou","year":"2014","journal-title":"Clin Sarcoma Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","article-title":"Uterine leiomyosarcoma: a review of the literature and update on management options","volume":"151","author":"Roberts","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104702_bib40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104702_bib42","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D\u2019Ambrosio","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104702_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2017.06.018","article-title":"Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: subgroup analysis of a phase 3, randomized clinical trial","volume":"146","author":"Hensley","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104702_bib44","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104702_bib45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14796694.2025.2463881","article-title":"Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas","volume":"21","author":"Assi","year":"2025","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib46","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104702_bib47","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104702_bib48","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104702_bib49","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S1470-2045(17)30672-1","article-title":"GeDDiS: insight into frontline therapy in soft tissue sarcoma","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1765319","article-title":"Treatment patterns and healthcare resource utilization among patients with advanced or metastatic soft tissue sarcoma in US community practices","volume":"2020","author":"Nadler","year":"2020","journal-title":"Sarcoma"},{"issue":"18","key":"10.1016\/j.ijgc.2026.104702_bib51","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104702_bib52","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/cncr.11730","article-title":"A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma","volume":"98","author":"Talbot","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104702_bib53","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/s41416-019-0462-1","article-title":"Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study","volume":"120","author":"Blay","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104702_bib55","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2023-256641","article-title":"\u03b2-hCG secreting uterine PEComa","volume":"17","author":"Murphy","year":"2024","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104702_bib57","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41379-021-00855-1","article-title":"Uterine PEComas: correlation between melanocytic marker expression and TSC alterations\/TFE3 fusions","volume":"35","author":"Bennett","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41379-021-00922-7","article-title":"TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition","volume":"35","author":"Chiang","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ijgc.2026.104702_bib59","article-title":"Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy","volume":"37","author":"Kyi","year":"2021","journal-title":"Gynecol Oncol Rep"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104702_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104702_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082870","article-title":"Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104702_bib62","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2026.104702_bib63","article-title":"Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma","volume":"39","author":"Lagos","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104702_bib64","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3390\/cancers12071873","article-title":"A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas","volume":"12","author":"Monga","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"suppl 15","key":"10.1016\/j.ijgc.2026.104702_bib65","article-title":"Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): report of LMS cohort","volume":"38","author":"Nathenson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104702_bib66","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/1078-0432.CCR-21-2001","article-title":"Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma","volume":"27","author":"Livingston","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35609","article-title":"Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09)","volume":"131","author":"Kim","year":"2025","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104702_bib68","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1158\/1078-0432.CCR-23-1137","article-title":"Safety, immunologic, and clinical activity of durvalumab in combination with olaparib or cediranib in advanced leiomyosarcoma: results of the DAPPER clinical trial","volume":"29","author":"Salawu","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.ijgc.2026.104702_bib69","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma","volume":"30","author":"Movva","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2022.07.031","article-title":"Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group","volume":"167","author":"Croce","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104702_bib71","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104702_bib72","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.ijgc.2026.104702_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1655","article-title":"PI3K\/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade","volume":"14","author":"De Wispelaere","year":"2024","journal-title":"Clin Transl Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104702_bib75","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104702_bib76","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 functional loss defines a targetable subset in leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ijgc.2026.104702_bib77","article-title":"Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors","volume":"9","author":"Rao","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-017-0451-x","article-title":"Activity of trabectedin and the PARP inhibitor Rucaparib in soft-tissue sarcomas","volume":"10","author":"Laroche","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104702_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101978","article-title":"Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets","volume":"35","author":"He","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104702_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102443","article-title":"53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma","volume":"9","author":"Pollack","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104702_bib81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0885-3924(02)00440-2","article-title":"Palliative Care: the World Health Organization\u2019s global perspective","volume":"24","author":"Sep\u00falveda","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104702_bib82","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104702_bib83","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.24.00542","article-title":"Palliative care for patients with cancer: ASCO guideline update","volume":"42","author":"Sanders","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104702_bib84","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13569-016-0060-4","article-title":"UK guidelines for the management of soft tissue sarcomas","volume":"6","author":"Dangoor","year":"2016","journal-title":"Clin Sarcoma Res"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104702_bib85","first-page":"389","article-title":"Palliative care outpatient interventions to limit aggressive care at end-of-life for patients with advanced soft tissue sarcomas","volume":"33","author":"Marret","year":"2025","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijgc.2026.104702_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/325189","article-title":"Symptom burden, survival and palliative care in advanced soft tissue sarcoma","volume":"2011","author":"Gough","year":"2011","journal-title":"Sarcoma"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12904-020-00702-1","article-title":"Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis","volume":"20","author":"Brandes","year":"2021","journal-title":"BMC Palliat Care"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104702_bib88","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.3390\/jcm11133756","article-title":"A systematic review and meta-analysis of the clinical use of megestrol acetate for cancer-related anorexia\/cachexia","volume":"11","author":"Lim","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104702_bib89","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1186\/s12885-018-4866-8","article-title":"Age-related sarcoma patient experience: results from a national survey in England","volume":"18","author":"Younger","year":"2018","journal-title":"BMC Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26002331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:23:34Z","timestamp":1785356614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26002331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X26002331"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104702","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-disciplinary management of advanced uterine sarcoma: a state of the art review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104702"}}